ClinicalTrials.govpublic full text
Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434
hepatic impairment, cirrhosis, sirna, monoclonal antibody, hdv, compensated cirrhosis, decompensated cirrhosis, interventional, phase1
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 894485
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.